We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins.